



We
follow the
science



and put
patients
first

SASB Index

SASB Standard: Biotechnology & Pharmaceuticals

This is an index to the location of our disclosures that align with the Sustainability Accounting Standards Board (SASB) standard for Biotechnology & Pharmaceuticals, version 2023-12. The report provides data from 1 January 2025 to 31 December 2025, unless otherwise stated.

| Metric Code | Metric | Disclosure Location |
|--|--|---|
| Safety of Clinical Trial Participants | | |
| HC-BP-210a.1 | Discussion, by region, of management process for ensuring quality and patient safety during clinical trials | Annual Report 2025, p. 31 Global Bioethics Standard pp. 2-4 |
| HC-BP-210a.2 | Number of inspections related to clinical trial management and pharmacovigilance that resulted in: (1) entity voluntary remediation or (2) regulatory or administrative actions taken against the entity | Not reported |
| HC-BP-210a.3 | Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries | To the extent we are aware of any material responsive matters, they would have been disclosed as part of our Annual Reports and Form 20-F Information, and quarterly updates thereto. |
| Access to Medicines | | |
| HC-BP-240a.1 | Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index | Annual Report 2025, p. 41 2024 Access to Medicines Index Report Card |
| HC-BP-240a.2 | List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP) | There are currently no prequalified products from AstraZeneca, when approved, products will be shown on the WHO PreQualified List . |
| Affordability & Pricing | | |
| HC-BP-240b.2 | Percentage change in: (1) weighted average list price and (2) weighted average net price across product portfolio compared to previous reporting period | Not reported |
| HC-BP-240b.3 | Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous reporting period | Not reported |
| Drug Safety | | |
| HC-BP-250a.1 | Products listed in public medical product safety or adverse event alert databases | Public medical product safety or adverse event alert databases, across major markets are as follows: <ul style="list-style-type: none"> • US: FDA Adverse Event Reporting System (FAERS) • UK: Yellow Card Scheme • EU: EudraVigilance • Japan: PMDA Adverse Reaction (ADR) Reporting System • China: National Centre for Adverse Drug Reaction Monitoring |
| HC-BP-250a.2 | Number of fatalities associated with products | Not reported |
| HC-BP-250a.3 | (1) Number of recalls issued, (2) total units recalled | Annual Report 2025, p. 31 |
| HC-BP-250a.4 | Total amount of product accepted for take-back, reuse, or disposal | Not reported |
| HC-BP-250a.5 | Number of enforcement actions taken in response to violations of good manufacturing practices (GMP) or equivalent standards, by type | Annual Report 2025, p. 31 |

| Metric Code | Metric | Disclosure Location |
|--|--|---|
| Counterfeit Drugs | | |
| HC-BP-260a.1 | Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting | SASB response: Counterfeit drugs |
| HC-BP-260a.2 | Discussion of process for alerting customers and business partners to potential or known risks associated with counterfeit products | SASB response: Counterfeit drugs |
| HC-BP-260a.3 | Number of actions that led to raids, seizure, arrests, or filing of criminal charges related to counterfeit products | Not reported |
| Ethical Marketing | | |
| HC-BP-270a.1 | Total amount of monetary losses as a result of legal proceedings associated with false marketing claims | To the extent we are aware of any material responsive matters, they would have been disclosed as part of our Annual Reports and Form 20-F Information, and quarterly updates thereto. |
| HC-BP-270a.2 | Description of code of ethics governing promotion of off-label use of products | Annual Report 2025, pp. 34-35 Global Standard Promoting our Products |
| Employee Recruitment, Development & Retention | | |
| HC-BP-330a.1 | Discussion of talent recruitment and retention efforts for scientists and research and development staff | Annual Report 2025, pp. 8, 26, 39, 228 |
| HC-BP-330a.2 | (1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others | Sustainability Data Annex 2025, p. 10 |
| Supply Chain Management | | |
| HC-BP-430a.1 | Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit programme or equivalent third-party audit programmes for integrity of supply chain and ingredients | AstraZeneca has an internal risk based supplier assessment system. In 2025 Global Quality Audit completed 520 internal quality audits of AstraZeneca suppliers and 76 internal quality audits of AstraZeneca sites. Sustainability Data Annex 2025, p. 10 |
| Business Ethics | | |
| HC-BP-510a.1 | Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery | To the extent we are aware of any material responsive matters, they would have been disclosed as part of our Annual Reports and Form 20-F Information, and quarterly updates thereto. |
| HC-BP-510a.2 | Description of code of ethics governing interactions with health care professionals | Annual Report 2025, pp. 34-35 AstraZeneca and Global Transparency |
| Activity Metrics | | |
| HC-BP-000.A | Number of patients treated | Annual Report 2025, p. 8 Patients treated is a subset of the people positively impacted metric. |
| HC-BP-000.B | Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3) | Our medicines Development Pipeline as at 10 February 2026 |

GRI Content Index

Statement of use

AstraZeneca has reported in accordance with the GRI Standards for the period 1 January 2025 - 31 December 2025. The list of material topics include all topics identified as material in the update to the 2024 double materiality assessment, conducted in 2025.

GRI 1 used

GRI 1: Foundation 2021

| GRI Standard | Disclosure | Location |
|---------------------------------|--|--|
| General Disclosures | | |
| GRI 2: General Disclosures 2021 | 2-1 Organizational details | Annual Report 2025, pp. Inside Front Cover (IFC), 192-196, 199, 223, 225 |
| | | The reporting covers AstraZeneca Group, unless otherwise stated. |
| | 2-2 Entities included in the organization's sustainability reporting | Annual Report 2025, pp. IFC, 192-196, 205, 212-213, 217-218, 219 Sustainability Data Reporting Criteria 2025 p. 2 |
| | 2-3 Reporting period, frequency and contact point | AstraZeneca publishes an annual report annually. The GRI Content Index was released on 8 April 2026. The index covers the reporting period 1 January 2025 to 31 December 2025, aligned to the reporting period for financial reporting. Questions about the report or reported information can be sent to disclosures@astrazeneca.com |
| | 2-4 Restatements of information | Annual Report 2025, p. 43 Sustainability Data Reporting Criteria 2025, p. 34 |
| | 2-5 External assurance | Annual Report 2025, pp. 83, 85, 220-221 |
| | 2-6 Activities, value chain and other business relationships | Annual Report 2025, pp. 8-9, 13, 17, 23, 27, 74-76 |
| | 2-7 Employees | Annual Report 2025, pp. 27, 39 |
| | 2-8 Workers who are not employees | Not reported |
| | 2-9 Governance structure and composition | Annual Report 2025, pp. 67-69, 71, 79-80 |
| | 2-10 Nomination and selection of the highest governance body | Annual Report 2025, pp. 79-80 |
| | 2-11 Chair of the highest governance body | Annual Report 2025, pp. 68-69 |
| | 2-12 Role of the highest governance body in overseeing the management of impacts | Annual Report 2025, pp. 67, 71-73, 74-76, 82, 83, 84, 90 Terms of Reference of the AstraZeneca Sustainability Committee |
| | 2-13 Delegation of responsibility for managing impacts | Annual Report 2025, pp. 67, 71-73, 74-76, 82, 83, 84, 90 Terms of Reference of the AstraZeneca Sustainability Committee |
| | 2-14 Role of the highest governance body in sustainability reporting | Annual Report 2025, pp. 82, 83, 84, 205 Terms of Reference of the AstraZeneca Sustainability Committee Terms of Reference of the AstraZeneca Audit Committee |
| | 2-15 Conflicts of interest | Annual Report 2025, p. 223 |
| | 2-16 Communication of critical concerns | Annual Report 2025, pp. 34-35, 73 |
| | 2-17 Collective knowledge of the highest governance body | Annual Report 2025, pp. 78, 79-80, 82 |
| | 2-18 Evaluation of the performance of the highest governance body | Annual Report 2025, p. 78 |
| 2-19 Remuneration policies | Annual Report 2025, pp. 73, 90-113 Remuneration Policy | |

| GRI Standard | Disclosure | Location |
|---|--|--|
| | 2-20 Process to determine remuneration | Annual Report 2025, pp. 73, 90-113 Remuneration Policy |
| | 2-21 Annual total compensation ratio | Annual Report 2025, p. 110 |
| | 2-22 Statement on sustainable development strategy | Annual Report 2025, pp. 3-5 |
| | 2-23 Policy commitments | Annual Report 2025, pp. 34-35, 205, 211, 217, 219 Code of Ethics Human Rights Statement |
| | 2-24 Embedding policy commitments | Code of Conduct for Third Parties Code of Ethics Human Rights Statement |
| | 2-25 Processes to remediate negative impacts | Annual Report 2025, pp. 34-35 Code of Conduct for Third Parties Code of Ethics Human Rights Statement |
| | 2-26 Mechanisms for seeking advice and raising concerns | Annual Report 2025, pp. 34-35 |
| | 2-27 Compliance with laws and regulations | Annual Report 2025, pp. 182-183, 185-187, 188 Sustainability Data Annex 2025, p. 6 |
| | 2-28 Membership associations | Annual Report 2025, pp. 31, 41, 45 Sustainability partnerships and alliances |
| | 2-29 Approach to stakeholder engagement | Annual Report 2025, pp. 39, 74-76, 78, 206-207 |
| | 2-30 Collective bargaining agreements | Annual Report 2025, p. 39 |
| Material topics | | |
| GRI 3: Material Topics 2021 | 3-1 Process to determine material topics | Annual Report 2025, pp. 74-76, 206-207 |
| | 3-2 List of material topics | Annual Report 2025, pp. 40, 206-207 |
| Sustainable innovation | | |
| GRI 3: Material Topics 2021 | 3-3 Management of material topics | Annual Report 2025, pp. 13, 17, 23, 28, 30, 74-76, 206, 217-218 |
| AstraZeneca specific disclosures | Number of new molecular entities (NMEs) approvals (cumulative) | Annual Report 2025, pp. 10, 217 |
| | Number of pipeline progression events | Annual Report 2025, pp. 11, 217 |
| | Number of regulatory events | Annual Report 2025, pp. 11, 217 |
| Patient safety and product quality | | |
| GRI 3: Material Topics 2021 | 3-3 Management of material topics | Annual Report 2025, pp. 31, 74-76, 206, 217-218 |
| AstraZeneca specific disclosures | Number of inspections from health authorities relating to Good Manufacturing Practice and Good Distribution Practice | Annual Report 2025 pp. 31, 218 |
| | Number of critical findings from health authorities relating to Good Manufacturing Practice and Good Distribution Practice | Annual Report 2025 pp. 31, 218 |
| | Number of product recalls | Annual Report 2025 pp. 31, 218 |
| Business conduct | | |
| GRI 3: Material Topics 2021 | 3-3 Management of material topics | Annual Report 2025, pp. 34-35, 74-76, 206, 211, 219 |

| GRI Standard | Disclosure | Location |
|---|---|--|
| Cybersecurity and data privacy | | |
| GRI 3: Material Topics 2021 | 3-3 Management of material topics | Annual Report 2025, pp. 36, 74-76, 206, 211, 219 |
| AstraZeneca specific disclosures | Number of material cybersecurity incidents | Annual Report 2025, pp. 36, 219 |
| | Number of material security breaches involving personal data | Annual Report 2025, pp. 36, 219 |
| People | | |
| GRI 3: Material Topics 2021 | 3-3 Management of material topics | Annual Report 2025, pp. 30, 36, 39, 74-76, 78, 206, 211, 217-218 |
| AstraZeneca specific disclosures | Employee belief that in the last 12 months, I have improved my existing skills, or learned new skills, or had a development opportunity | Annual Report 2025, pp. 39, 218 |
| | Employee belief that AstraZeneca is a great place to work | Annual Report 2025, pp. 39, 218 |
| Accessible and affordable healthcare | | |
| GRI 3: Material Topics 2021 | 3-3 Management of material topics | Annual Report 2025, pp. 41, 74-76, 206, 217-218 |
| AstraZeneca specific disclosures | Number of people positively impacted | Annual Report 2025, pp. 41, 218 |
| | Number of people positively impacted from underserved groups | Annual Report 2025, pp. 41, 218 |
| Climate change | | |
| GRI 3: Material Topics 2021 | 3-3 Management of material topics | Annual Report 2025, pp. 42-44, 74-76, 206, 211-213 |
| GRI 201: Economic performance 2016 | 201-2 Financial implications and other risks and opportunities due to climate change | Annual Report 2025, pp. 42-44, 47, 206 |
| | 305-1 Direct (Scope 1) GHG emissions | Annual Report 2025, pp. 42, 43, 212-213 |
| GRI 305: Emissions 2016 | 305-2 Energy indirect (Scope 2) GHG emissions | Annual Report 2025, pp. 42, 43, 212-213 |
| | 305-3 Other indirect (Scope 3) GHG emissions | Annual Report 2025, pp. 42, 43, 212-213 |
| | 305-4 GHG emissions intensity | Annual Report 2025, pp. 42, 43, 212-213 |
| Nature | | |
| GRI 3: Material Topics 2021 | 3-3 Management of material topics | Annual Report 2025, pp. 45, 74-76, 206, 211 |